Skip to main content
SpringerLink
Log in

TNF-based isolated limb perfusion: A decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas

  • Chapter
Targeting Treatment of Soft Tissue Sarcomas

Part of the book series: Cancer Treatment and Research ((CTAR,volume 120))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clincopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317–1327

    CAS  PubMed  Google Scholar 

  2. Potter DA, Kinsella D, Gladstein E et al. High grade soft tissue sarcomas of the extremities. Cancer 1986;59:190–205

    Google Scholar 

  3. Stotter AT, A’Hearn RP, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990;65:1119–1129

    CAS  PubMed  Google Scholar 

  4. Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991;67:2083–2086

    CAS  PubMed  Google Scholar 

  5. Landis S, Murray T, Bolden S, Wingo P. Cancer Statistics, 1999. CA Cancer J Clin 1999;9:8–26

    Google Scholar 

  6. Suit HD, Proppe KH, Mankin HJ, Wood WC. Preoperative radiation therapy for sarcoma of soft tissue. Cancer 47:2269–2274, 1981

    CAS  PubMed  Google Scholar 

  7. Eilber FR, Mirra JJ, Grant T, Weisenburger T, Morton DL. Is amputation necessary for sarcoma: a 7-year experiment with limb salvage. Ann Surg 1980;192:431–437

    CAS  PubMed  Google Scholar 

  8. Eilber FR, Morton DL, Eckhardt J, Grant T, Weisenburger T. Limb salvage for skeletal and soft-tissue sarcomas: multidisciplinary preoperative therapy. Cancer 1984;53:2579–2584

    CAS  PubMed  Google Scholar 

  9. Shiu MH, Hilaris BS, Harrison LB, Brennan MF. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991;21:1485–1492

    CAS  PubMed  Google Scholar 

  10. Creech O, Krementz E, Ryan E, Winblad J. Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg 1958;148:616–632

    PubMed  Google Scholar 

  11. Benckhuijsen C, Kroon BB, van Geel AN, et al: Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157–63

    CAS  PubMed  Google Scholar 

  12. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma — effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992;16:227–233

    CAS  PubMed  Google Scholar 

  13. Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1124–1126

    CAS  PubMed  Google Scholar 

  14. Wieberdink K, Benckhuijsen C, Braat RP, Van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905–910

    Article  CAS  PubMed  Google Scholar 

  15. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977;185(5):555–564

    CAS  PubMed  Google Scholar 

  16. Muchmore JH, Carter RD, Krementz ET. Regional perfusion for malignant melanoma and soft tissue sarcoma: a review. Cancer Invest. 1985;3:129–143

    CAS  PubMed  Google Scholar 

  17. Pommier RF, Moseley HS, Cohen J et al. Pharmacokinetics, Toxicity, and Short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg 155:667–671, 1988

    CAS  PubMed  Google Scholar 

  18. Klaase JM, Kroon BBR, Benckhuysen C, Van Geel AN, Albus-Lutter ChE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 64:616–621, 1989

    CAS  PubMed  Google Scholar 

  19. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 73:2140–2146, 1994

    CAS  PubMed  Google Scholar 

  20. Lienard D, Ewalenko, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:50–62

    Google Scholar 

  21. Eggermont AMM, Liénard D, Schraffordt Koops H, Rosenkaimer F, Lejeune FJ. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-a in combination with gamma-Interferon and melphalan. Fiers W and Buurman WA (eds), In: Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, Basel, Karger Verlag, 1993, pp 239–243

    Google Scholar 

  22. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80:995–997

    CAS  PubMed  Google Scholar 

  23. Eggermont AMM, Schraffordt Koops H, Lienard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [see comments]. J Clin Oncol 14:2653–65, 1996a

    CAS  PubMed  Google Scholar 

  24. Santinami M, Deraco M, Azzarelli A, Cascinelli F, Chiti A, Costagli V, Manzi R, Quagliolo V, Rebuffoni G, Santoro N, Vaglini M. Treatment of recurrent sarcoma of the extremities by isolated perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996;82:579–84

    CAS  PubMed  Google Scholar 

  25. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224:756–64; discussion 764-5, 1996b

    Article  CAS  PubMed  Google Scholar 

  26. Gutman M, Inbar M, Lev-Shlush D, Mozes M, Chaitchik S, Meller I, Klausner JM. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation. Cancer 1997;79:1129–37

    Article  CAS  PubMed  Google Scholar 

  27. Eggermont AMM, Schraffordt Koops H, Klausner JM, Schlag PM, Kroon BBR, Gustafson P, Steinmann G, Lejeune FJ. Limb Salvage by Isolation Limb Perfusion with Tumor Necrosis Factor Alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proceed ASCO 1999;11:497 (abstract)

    Google Scholar 

  28. Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza M, Azzarelli A, Pilati P, Mocellin S, Lise M. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer, 1999;86:1742–9

    CAS  PubMed  Google Scholar 

  29. Lejeune FJ, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000, 26:669–78

    Article  CAS  PubMed  Google Scholar 

  30. Hohenberger P, Kettelhack C, Hermann A, Schlag PM. Functional outcome after preoperative isolated limb perfusion with rhTNFalpha/Melphalan for high-grade extremity sarcoma. Eur J Cancer 2001;37(6):S34–35

    Google Scholar 

  31. Lans TE, deWilt JHW, van Geel AN, Eggermont AMM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable stewart-treves lymphangiosarcoma. Ann Surg Oncol. 2002;9:1004–9

    CAS  PubMed  Google Scholar 

  32. Noorda EM, Vrouwenraets BC, Nieweg OE, Slooten GW, Kroon BBR. Isolated limb perfusion with TNFα and Melphalan for Irresectable Soft Tissue Sarcoma of the Extremities. Ann Surg Oncol 2003;10;1:S36

    Google Scholar 

  33. Bonvalot S, Lejeune F, Laplanche A, Stoeckle E, Le Pechoux C, Vanei D, Lumbroso J, Terrier P, Aubert B, LeCesne A. Limb slavage by isolated limb perfusion (iILP) in patients with locally advanced soft tissue sarcoma (ASTS): a randomized phase II study comparing 4 doses of TNFα Proc. Am Soc Clin Oncol, 2003;22:823

    Google Scholar 

  34. Grünhagen D, Lans TE, de Wilt JHW, van Geel AN, Eggermont AMM. Management of Local Recurrences of Soft Tissue Sarcomas in an Irradiated Field after Prior Surgery and Radiotherapy: the Role of TNF-based Isolated Limb Perfusions to achieve Limb Salvage. Eur J Cancer 2003;39:in press

    Google Scholar 

  35. Etten van B, van Geel AN, de Wilt JHW, Eggermont AMM. Fifty Tumor Necrosis Factor-based Isolated Limb Perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other exremity tumors. Ann Surg Oncol, 2003;27:32–37

    Google Scholar 

  36. Vrouwenraets BC, Kroon BBR, Ogilvie AC, Van Geel AN, Nieweg OE, Swaak AJG, Eggermont AMM. Absence of severe systemic toxicity after laekage controlled isolated limb perfusion with Tumor Necrosis Factor alpha and melphalan. Ann Surg Oncol, 1999;6:405–412

    Google Scholar 

  37. Stam, T. C., Swaak, A. J., de Vries, M. R., ten Hagen, T. L., Eggermont, A. M. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage [In Process Citation] Ann Surg Oncol, 2000;4:268–75

    Google Scholar 

  38. Vrouenraets BC, Eggermont AMM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, Kroon BBR. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27:390–5

    Article  CAS  PubMed  Google Scholar 

  39. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1993; 29A:606–612

    CAS  PubMed  Google Scholar 

  40. Eggermont AMM, Liénard D, Schraffordt Koops H, Kroon BBR, Rosenkaimer F, Klaase JM, Schmitz PIM, Lejeune FJ. High dose tumor necrosis factor-alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat, 7:32–36, 1995

    Google Scholar 

  41. Eggermont AMM. Treatment of melanoma intransit metastases confined to the limb. Cancer Surveys, 26:335–349, 1996

    CAS  PubMed  Google Scholar 

  42. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol, 1996;14:479–89

    CAS  PubMed  Google Scholar 

  43. Lienard D, Eggermont AMM, Schraffordt Koops H, Kroon BBR, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res, 1999;9:491–502

    CAS  PubMed  Google Scholar 

  44. Olieman, A.F., Lienard, D., Eggermont, A.M., Kroon, B.B., Lejeune, F.J., Hoekstra, H.J. & Koops, H.S. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg, 1999;134, 303–7

    CAS  PubMed  Google Scholar 

  45. Bickels, J., Manusama, E.R., Gutman, M., Eggermont, AMM, Kollender, Y., Abu-Abid, S., Van Geel, A.N., Lev-Shlush, D., Klausner, J.M. & Meller, I. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity [In Process Citation]. Eur J Surg Oncol, 1999;25:509–14

    Article  CAS  PubMed  Google Scholar 

  46. Lev-Chelouche D, Abu-Abeid S, Nakache R, Issakov J, Kollander Y, Merimsky O, Meller I, Klausner JM, Gutman M. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery 1999;126:963–967

    CAS  PubMed  Google Scholar 

  47. Sijens PE, Eggermont AMM, Van Dijk P, Oudkerk M. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose YNFα+ melphalan isolated limb perfusion. NMR in Biomedicine 1995;18:215–224

    Google Scholar 

  48. Renard N, Liénard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer 1994;57:656–663

    CAS  PubMed  Google Scholar 

  49. Nooijen PTGA, Eggermont AMM, Schalkwijk L, Henzen-Logmans S, DeWaal RMW, Ruiter DJ. Complete response of melanoma in-transit metastasis after isolated limb perfusion with tumor necrosis factor-alpha and melphalan without massive tumor necrosis: clinical and histopathological study of the delayed-type reaction patterns. Cancer Res 1998;58:4880–4887

    CAS  PubMed  Google Scholar 

  50. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Synergistic antitumour effect of recombinant human tumour necrosis factor with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551–555

    CAS  PubMed  Google Scholar 

  51. Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996;22:152–157

    Article  CAS  PubMed  Google Scholar 

  52. De Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AMM. Tumour Necrosis Factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–1003

    PubMed  Google Scholar 

  53. Veen vd AH, Wilt de JHW, Eggermont AMM, van Tiel ST, ten Hagen TLM. TNF-α augments intratumoural concentration of doxorubicin in TVF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer, 2000;82:973–980

    Google Scholar 

  54. B van Etten, M de Vries, M van IJken, T Lans, G Guetens, G Ambagtsheer, S van Tiel, G de Boeck, E de Bruijn, AMM Eggermont AMM, TLM Ten Hagen. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-based isolated hepatic perfusion. Br J Cancer. 2003;87:314–9

    Google Scholar 

  55. Kristensen CA, Nozue M, Boucher Y and Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996;74:533–536.

    CAS  PubMed  Google Scholar 

  56. Manusama ER, Nooijen PTGA, Stavast J, de Wilt JHW, Marquet RL and Eggermont AMM. Assessment of the role of neutrophils on the antitumor effect of TNFα in an in vivo isolated limb perfusion model in sarcoma-bearing Brown Norway rats. J Surg Res 1998;78:169–175

    Article  CAS  PubMed  Google Scholar 

  57. DeWilt JHW, Manusama ER, van Tiel ST, van IJken MGA, ten Hagen TLM, Eggermont AMM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor-alpha and melphalan in rats. Br J Cancer 1999;80:161–166

    CAS  Google Scholar 

  58. Manusama ER, de Wilt JHW, ten Hagen TLM, Marquet RL, Eggermont AMM. Toxicity and antitumor activity of interferon-gamma alone and in combinations with TNF and Melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 1999;6:173–177

    CAS  PubMed  Google Scholar 

  59. Seynhaeve ALB, de Wilt JHW, vanTiel SA, Eggermont AMM, ten Hagen TLM. Combination of Actinomycin D with TNF-a in Isolated Limb Perfusion results in improved tumour response in soft tissue sarcoma-bearing rats but is accompanied by severe dose limiting local toxicity. Br J Cancer 2002; 86:1174–1179.

    Article  CAS  PubMed  Google Scholar 

  60. DeWilt JHW, Manusama ER, van Etten B, van Tiel ST, Jorna AS, Seynhaeve ALB, ten Hagen TLM, Eggermont AMM: Inhibition of Nitric Oxide Synthesis by L-NAME results in synergistic antitumour activity with melpahlan and tumour necrosis factor-alpha-based isolated limb. Br J Cancer, 2000:83: 1176–11

    PubMed  Google Scholar 

  61. Brunstein F, Hoving S, van Tiel S, ten Hagen TLM, Eggermont AMM. Synergistic antitumor activity of histamine in combination with chemotherapy in the regional treatment of soft tissue sarcomas. Eur J Cancer 2003;39:in press

    Google Scholar 

  62. Ten Hagen TLM, FJ Lejeune, Eggermont AMM. TNF is here to stay — Revisited, Trends in Immunology (Formerly Immunology Today), 2001;22:127–129

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA, Rotterdam, The Netherlands

    Dirk J Grünhagen, Flavia Brunstein, Timo L.M. ten Hagen, Albertus N. van Geel, Johannes H.W. de Wilt & Alexander M.M. Eggermont MD, PhD (Professor Surgical Oncology, Head of Department)

Authors
  1. Dirk J Grünhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Flavia Brunstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timo L.M. ten Hagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albertus N. van Geel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johannes H.W. de Wilt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexander M.M. Eggermont MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Jaap Verweij

  2. Department of Medical Oncology, Free University Medical Center, Amsterdam, The Netherlands

    Herbert M. Pinedo

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Grünhagen, D.J., Brunstein, F., ten Hagen, T.L., van Geel, A.N., de Wilt, J.H., Eggermont, A.M. (2004). TNF-based isolated limb perfusion: A decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. In: Verweij, J., Pinedo, H.M. (eds) Targeting Treatment of Soft Tissue Sarcomas. Cancer Treatment and Research, vol 120. Springer, Boston, MA. https://doi.org/10.1007/1-4020-7856-0_4

Download citation

  • DOI: https://doi.org/10.1007/1-4020-7856-0_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7808-8

  • Online ISBN: 978-1-4020-7856-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation